Clinical trial
Randomised Phase II Study Evaluating the Anti-tumour Activity, Safety and Pharmacology of Two Dose Regimens of IPH2101, a Human Monoclonal Anti-KIR Antibody, in Patients With Multiple Myeloma in Stable Partial Response After a First Line Therapy
NCT00999830 is registered in ClinicalTrials.gov with Innate Pharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomised Phase II Study Evaluating the Anti-tumour Activity, Safety and Pharmacology of Two Dose Regimens of IPH2101, a Human Monoclonal Anti-KIR Antibody, in Patients With Multiple Myeloma in Stable Partial Response After a First Line Therapy
- Lead sponsor
- Innate Pharma
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2009
- Completion date
- June 30, 2013
- Enrollment
- 27 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.